September 24, 2007—Hologic Inc, a leading provider of diagnostic imaging and state-of-the-art digital imaging systems directed towards women’s health, recently announced it had completed the acquisition of BioLucent Inc, developer of the MammoPad breast cushion.

“This acquisition reflects our continued strategy and efforts to offer a comprehensive portfolio of products to serve in the breast cancer detection market,” said Jack Cumming, Chairman and CEO of Hologic. “The BioLucent MammoPad was designed to benefit women undergoing mammograms by providing more comfort, we believe better tissue acquisition and ultimately improved outcomes. It is our hope with proper training and support, the MammoPad can become a standard of care in mammography. We look forward to the opportunities that will develop from this combination as we continue to build value for our shareholders.”

Prior to the acquisition, BioLucent completed the spin-off its brachytherapy technology and business to the holders of BioLucent’s outstanding shares of capital stock. The new company, Cianna Medical, will manufacture and market the SAVI applicator. As a result Hologic acquired BioLucent’s Mammopad business and related assets.

The aggregate purchase price paid by Hologic to the security holders of BioLucent at the closing of the acquisition, exclusive of certain transaction costs and expenses, was approximately $70 million.